Vanda Pharmaceuticals “perplexed” by FDA rejection of jet lag drug

The FDA has issued a dreaded Complete Response Letter to Vanda Pharmaceuticals, rejecting the company’s jet lag drug Hetlioz (tasimelteon).

Washington DC-based Vanda said that the regulator had ruled that the measures used in trials to demonstrate improved sleep are of “unclear clinical significance”.